Free Trial
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

Veracyte logo
$27.38 +0.57 (+2.13%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$27.50 +0.12 (+0.42%)
As of 06/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Veracyte Stock (NASDAQ:VCYT)

Key Stats

Today's Range
$26.52
$27.64
50-Day Range
$26.39
$32.23
52-Week Range
$19.73
$47.32
Volume
3.60 million shs
Average Volume
913,642 shs
Market Capitalization
$2.14 billion
P/E Ratio
66.78
Dividend Yield
N/A
Price Target
$40.90
Consensus Rating
Moderate Buy

Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Veracyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

VCYT MarketRank™: 

Veracyte scored higher than 69% of companies evaluated by MarketBeat, and ranked 322nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Veracyte has only been the subject of 3 research reports in the past 90 days.

  • Read more about Veracyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veracyte is 66.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.00.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veracyte is 66.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.

  • Price to Book Value per Share Ratio

    Veracyte has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Veracyte's valuation and earnings.
  • Percentage of Shares Shorted

    7.69% of the float of Veracyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Veracyte has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Veracyte does not currently pay a dividend.

  • Dividend Growth

    Veracyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.69% of the float of Veracyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Veracyte has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Veracyte has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Veracyte this week, compared to 7 articles on an average week.
  • Search Interest

    1 people have searched for VCYT on MarketBeat in the last 30 days.
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Veracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

VCYT Stock Analysis - Frequently Asked Questions

Veracyte's stock was trading at $39.60 at the beginning of 2025. Since then, VCYT shares have decreased by 30.9% and is now trading at $27.38.
View the best growth stocks for 2025 here
.

Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a net margin of 7.13% and a trailing twelve-month return on equity of 6.14%.
Read the conference call transcript
.

The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
2/24/2025
Today
6/30/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VCYT
Employees
790
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$40.90
High Stock Price Target
$50.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+49.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
66.78
Forward P/E Ratio
40.26
P/E Growth
N/A
Net Income
$24.14 million
Pretax Margin
7.57%

Debt

Sales & Book Value

Annual Sales
$445.76 million
Cash Flow
$1.04 per share
Price / Cash Flow
26.41
Book Value
$15.17 per share
Price / Book
1.80

Miscellaneous

Free Float
77,219,000
Market Cap
$2.14 billion
Optionable
Optionable
Beta
2.10

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:VCYT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners